e-engineering the clinical pproach to suspected cardiac chest ain assessment n the emergency epartment by epediting research evidence to practice using rtificial ntelligence. (RAPIDx AI)—a cluster randomized study design - 07/04/25
ABSTRACT |
Background |
Clinical work-up for suspected cardiac chest pain is resource intensive. Despite expectations, high-sensitivity cardiac troponin assays have not made decision making easier. The impact of recently validated rapid triage protocols including the 0-hour/1-hour hs-cTn protocols on care and outcomes may be limited by the heterogeneity in interpretation of troponin profiles by clinicians. We have developed machine learning (ML) models which digitally phenotype myocardial injury and infarction with a high predictive performance and provide accurate risk assessment among patients presenting to EDs with suspected cardiac symptoms. The use of these models may support clinical decision-making and allow the synthesis of an evidence base particularly in non-T1MI patients however prospective validation is required.
Objective |
We propose that integrating validated real-time artificial intelligence (AI) methods into clinical care may better support clinical decision-making and establish the foundation for a self-learning health system.
Design |
This prospective, multicenter, open-label, cluster-randomized clinical trial within blinded endpoint adjudication across 12 hospitals (n = 20,000) will randomize sites to the clinical decision-support tool or continue current standard of care. The clinical decision support tool will utilize ML models to provide objective patient-specific diagnostic probabilities (ie, likelihood for Type 1 myocardial infarction [MI] versus Type 2 MI/Acute Myocardial Injury versus Chronic Myocardial Injury etc.) and prognostic assessments. The primary outcome is the composite of cardiovascular mortality, new or recurrent MI and unplanned hospital re-admission at 12 months post index presentation.
Summary |
Supporting clinicians with a decision support tool that utilizes AI has the potential to provide better diagnostic and prognostic assessment thereby improving clinical efficiency and establish a self-learning health system continually improving risk assessment, quality and safety.
Trial registration |
ANZCTR, Registration Number: ACTRN12620001319965, www.anzctr.org.au/.
Le texte complet de cet article est disponible en PDF.Plan
Vol 285
P. 106-118 - juillet 2025 Retour au numéro
Article précédent
- Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT
- Mia Ravn Jacobsen, Reza Jabbari, Erik Lerkevang Grove, Michael Mæng, Karsten Veien, Mikkel Hougaard, Philip Freeman, Henning Kelbæk, Mette Gitz Charlot, Thomas Engstrøm, Rikke Sørensen
- Ventricular-arterial coupling is associated with clinical outcomes in patients with systemic right ventricle
- Giulia Pasqualin, Amrit Misra, Kimberlee Gauvreau, Stephen P. Sanders, Akshay S. Desai, Alex Alexander, Ashwin Prakash, Michael M. Givertz, Anne Marie Valente
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?